Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1983 Mar;80(5):1454–1458. doi: 10.1073/pnas.80.5.1454

Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy.

A F Stewart, K L Insogna, D Goltzman, A E Broadus
PMCID: PMC393616  PMID: 6298791

Abstract

Humoral hypercalcemia of malignancy (HHM) most commonly results from secretion by tumors of an unidentified circulating calcemic factor that appears in clinical studies to stimulate both a parathyroid hormone (PTH)-sensitive proximal tubular adenylate cyclase and a distinct PTH-sensitive renal tubular glucose-6-phosphate dehydrogenase complex. In the present study, 8 M urea extracts of tumors from patients with HHM have been shown to contain both in vitro adenylate cyclase-stimulating activity and glucose-6-phosphate dehydrogenase-stimulating activity as detected in a sensitive cytochemical bioassay. Both the adenylate cyclase-stimulating activity and cytochemical bioactivity are due to specific binding of a substance in the tumor extracts to renal PTH receptors, as demonstrated by competitive inhibition studies using the bovine PTH fragment analogue [Nle8,18, Tyr34]bPTH-(3-34) amide. Preincubation with an antiserum to PTH results in no loss of activity in the tumor extract, and the activity appears both on gel filtration and ultrafiltration to be far larger than PTH (estimated Mr 70,000). These studies demonstrate that extracts of tumors from patients with HHM contain a substance that binds to the PTH receptors in the nephron responsible for activation of both the PTH-sensitive glucose-6-phosphate dehydrogenase and the PTH-sensitive adenylate cyclase. This substance is chromatographically and immunologically distinct from PTH. Its role in the genesis of HHM requires further study.

Full text

PDF
1454

Images in this article

1457Image
on p.1457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson R. C., Jr, Riggs B. L., Pickard B. M., Arnaud C. D. Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism. J Clin Invest. 1974 Jul;54(1):175–181. doi: 10.1172/JCI107739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benson R. C., Jr, Riggs B. L., Pickard B. M., Arnaud C. D. Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. Am J Med. 1974 Jun;56(6):821–826. doi: 10.1016/0002-9343(74)90810-9. [DOI] [PubMed] [Google Scholar]
  3. Brenner D. E., Harvey H. A., Lipton A., Demers L. A study of prostaglandin E2, parathormone, and response to indomethacin in patients with hypercalcemia of malignancy. Cancer. 1982 Feb 1;49(3):556–561. doi: 10.1002/1097-0142(19820201)49:3<556::aid-cncr2820490327>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  4. Goltzman D., Goltzmann D., Peytremann A., Callahan E., Tregear G. W., Potts J. T., Jr Analysis of the requirements for parathyroid hormone action in renal membranes with the use of inhibiting analogues. J Biol Chem. 1975 Apr 25;250(8):3199–3203. [PubMed] [Google Scholar]
  5. Goltzman D., Henderson B., Loveridge N. Cytochemical bioassay of parathyroid hormone: characteristics of the assay and analysis of circulating hormonal forms. J Clin Invest. 1980 Jun;65(6):1309–1317. doi: 10.1172/JCI109794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goltzman D., Stewart A. F., Broadus A. E. Malignancy-associated hypercalcemia: evaluation with a cytochemical bioassay for parathyroid hormone. J Clin Endocrinol Metab. 1981 Nov;53(5):899–904. doi: 10.1210/jcem-53-5-899. [DOI] [PubMed] [Google Scholar]
  7. Hirshorn J. E., Vrhovsek E., Posen S. Carcinoma of the breast associated with hypercalcemia and the presence of parathyroid hormone-like substances in the tumor. J Clin Endocrinol Metab. 1979 Feb;48(2):217–221. doi: 10.1210/jcem-48-2-217. [DOI] [PubMed] [Google Scholar]
  8. Kukreja S. C., Shemerdiak W. P., Lad T. E., Johnson P. A. Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer. J Clin Endocrinol Metab. 1980 Jul;51(1):167–169. doi: 10.1210/jcem-51-1-167. [DOI] [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Lafferty F. W. Pseudohyperparathyroidism. Medicine (Baltimore) 1966 May;45(3):247–260. doi: 10.1097/00005792-196605000-00004. [DOI] [PubMed] [Google Scholar]
  11. Mallette L. E., Bradley W. A. Bovine parathyroid hormone-(41-84), a hormone fragment with desirable properties for use as radioligand. J Lab Clin Med. 1981 Dec;98(6):886–895. [PubMed] [Google Scholar]
  12. Metz S. A., McRae J. R., Robertson R. P. Prostaglandins as mediators of paraneoplastic syndromes: review and up-date. Metabolism. 1981 Mar;30(3):299–316. doi: 10.1016/0026-0495(81)90156-6. [DOI] [PubMed] [Google Scholar]
  13. Minkin C., Fredericks R. S., Pokress S., Rude R. K., Sharp C. F., Jr, Tong M., Singer F. R. Bone resorption and humoral hypercalcemia of malignancy: stimulation of bone resorption in vitro by tumor extracts is inhibited by prostaglandin synthesis inhibitors. J Clin Endocrinol Metab. 1981 Nov;53(5):941–947. doi: 10.1210/jcem-53-5-941. [DOI] [PubMed] [Google Scholar]
  14. Nissenson R. A., Abbott S. R., Teitelbaum A. P., Clark O. H., Arnaud C. D. Endogenous biologically active human parathyroid hormone: measurement by a guanyl nucleotide-amplified renal adenylate cyclase assay. J Clin Endocrinol Metab. 1981 May;52(5):840–846. doi: 10.1210/jcem-52-5-840. [DOI] [PubMed] [Google Scholar]
  15. Powell D., Singer F. R., Murray T. M., Minkin C., Potts J. T., Jr Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases. N Engl J Med. 1973 Jul 26;289(4):176–181. doi: 10.1056/NEJM197307262890403. [DOI] [PubMed] [Google Scholar]
  16. Robertson R. P., Baylink D. J., Metz S. A., Cummings K. B. Plasma prostaglandin E in patients with cancer with and without hypercalcemia. J Clin Endocrinol Metab. 1976 Dec;43(6):1330–1335. doi: 10.1210/jcem-43-6-1330. [DOI] [PubMed] [Google Scholar]
  17. Rosenblatt M., Callahan E. N., Mahaffey J. E., Pont A., Potts J. T., Jr Parathyroid hormone inhibitors. Design, synthesis, and biologic evaluation of hormone analogues. J Biol Chem. 1977 Aug 25;252(16):5847–5851. [PubMed] [Google Scholar]
  18. Rude R. K., Sharp C. F., Jr, Fredericks R. S., Oldham S. B., Elbaum N., Link J., Irwin L., Singer F. R. Urinary and nephrogenous adenosine 3',5'-monophosphate in the hypercalcemia of malignancy. J Clin Endocrinol Metab. 1981 Apr;52(4):765–771. doi: 10.1210/jcem-52-4-765. [DOI] [PubMed] [Google Scholar]
  19. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974 Apr;58(2):541–548. doi: 10.1016/0003-2697(74)90222-x. [DOI] [PubMed] [Google Scholar]
  20. Seyberth H. W., Segre G. V., Morgan J. L., Sweetman B. J., Potts J. T., Jr, Oates J. A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med. 1975 Dec 18;293(25):1278–1283. doi: 10.1056/NEJM197512182932502. [DOI] [PubMed] [Google Scholar]
  21. Sherwood L. M. The multiple causes of hypercalcemia in malignant disease. N Engl J Med. 1980 Dec 11;303(24):1412–1413. doi: 10.1056/NEJM198012113032409. [DOI] [PubMed] [Google Scholar]
  22. Stewart A. F., Horst R., Deftos L. J., Cadman E. C., Lang R., Broadus A. E. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med. 1980 Dec 11;303(24):1377–1383. doi: 10.1056/NEJM198012113032401. [DOI] [PubMed] [Google Scholar]
  23. Stewart A. F., Vignery A., Silverglate A., Ravin N. D., LiVolsi V., Broadus A. E., Baron R. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab. 1982 Aug;55(2):219–227. doi: 10.1210/jcem-55-2-219. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES